Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.

Body weight showed a numerical trend towards a benefit with iGlarLixi versus IDegAsp, but a difference between treatment arms was only observed in HOMA‐β Q2 (LSM difference −1.73 kg; p = 0.033). 3.4.

also in 1,012 other papers

Across all HOMA‐β quartiles, similar reductions in FPG were observed in the iGlarLixi and IDegAsp arms, while PPG reductions showed a trend towards being greater with iGlarLixi versus IDegAsp. 3.3.

also in 53,322 other papers

Furthermore, the magnitude of the between‐treatment difference in insulin dose exhibited an increasing trend corresponding to higher β‐cell functional capacity, further emphasising the benefits of iGlarLixi over IDegAsp to provide consistent glycaemic efficacy across all levels of β‐cell function without the need for large increases in insulin dose.

also in 63,971 other papers